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ABSTRACT
Background: Diabetes and metabolic syndromes are chronic, devastating diseases with increasing prevalence. Human pluripotent stem cells
are gaining popularity in their usage for human in vitro disease modeling. With recent rapid advances in genome editing tools, these cells can now
be genetically manipulated with relative ease to study how genes and gene variants contribute to diabetes and metabolic syndromes.
Scope of review: We highlight the diabetes and metabolic genes and gene variants, which could potentially be studied, using two powerful
technologies e human pluripotent stem cells (hPSCs) and genome editing tools e to aid the elucidation of yet elusive mechanisms underlying
these complex diseases.
Major conclusions: hPSCs and the advancing genome editing tools appear to be a timely and potent combination for probing molecular
mechanism(s) underlying diseases such as diabetes and metabolic syndromes. The knowledge gained from these hiPSC-based disease modeling
studies can potentially be translated into the clinics by guiding clinicians on the appropriate type of medication to use for each condition based on
the mechanism of action of the disease.
 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. INTRODUCTION
Diabetes andmetabolic syndromes are chronic devastating diseaseswith
increasing prevalence. Although a subset of patients develops diabetes
and metabolic syndromes due to monogenic mutations, a majority are
due to complex gene-environment interactions. Human pluripotent stem
cells are gaining popularity in their usage for human in vitro disease
modeling. With recent rapid advances in genome editing tools, these cells
can now be genetically manipulated with relative ease. In this review, we
highlight the diabetes and, metabolic genes and gene variants which
could potentially be studied using these two powerful technologies (hu-
man pluripotent stemcells and genomeediting tools) to aid the elucidation
of currently elusive mechanisms underlying these complex diseases.
2. INCREASED USAGE OF HUMAN PLURIPOTENT STEM CELLS
(hPSCs) FOR HUMAN IN VITRO DISEASE MODELING
Since their discovery in 2007 [1], human induced pluripotent stem
cells (hiPSCs) have become a major focus of research [2]. In terms of
using hiPSCs for understanding human disease mechanisms,
numerous hiPSCs have been generated from patients with a wide
variety of diseases [3]. Many of these hiPSCs have been derived from
patients with single gene mutations as these monogenic diseases are
those that can be modeled with the greatest ease. However, complex
diseases such as diabetic cardiomyopathy can also be potentially
modeled in vitro [4].
Diabetes, one of the most common metabolic disorders, is a major
cause of increased morbidity and mortality for which a cure remains
elusive. Classical methodologies for studying diabetes disease mech-
anisms, such as the use of rodent models, provide signiﬁcant insights
into disease biology. However, it is also known that rodent models do not
fully recapitulate the diabetes phenotype in humans, for instance in
several types ofmaturity onset diabetes of the young (MODY) (autosomal
dominant) conditions (mice with heterozygous mutations do not develop
diabetes) [5] and Wolfram Syndrome [6]. Therefore, hiPSCs could be
derived from patients with these forms of diabetes and differentiated
into pancreatic beta cells to serve as suitable alternative human models
for diabetes research [7,8,105]. To further understand the etiology of
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more common forms of diabetes, hiPSCs have been derived from both
type 1 diabetes (T1D) and type 2 diabetes (T2D) patients [9e11].
However, due to its complexity, T1D and T2D have yet to be convincingly
modeled in vitro with these hiPSCs [12]. In this review, we propose and
discuss the use of genome editing tools to generate hiPSCs carrying
speciﬁc gene variants associated with diabetes along with isogenic
controls. Once these hiPSCs have been derived, they can then be
differentiated into various cell types relevant to diabetes, such as
pancreatic cells, skeletal myocytes, adipocytes and hepatocytes, in
order to study their biology and for drug screening purposes.
3. ADVANCES IN GENOME EDITING TOOLS THAT CAN BE
APPLIED TO HUMAN PLURIPOTENT STEM CELL BIOLOGY
Genome editing, the genetic engineering (insertion, deletion or
replacement) of DNA, is an approach to understand the function of a
gene of interest. Genome editing tools such as the conventional ho-
mologous recombination (HR), or the more advanced (and advancing)
tools such as zinc ﬁnger nucleases (ZFNs), transcription activator-like
effector nucleases (TALENs) or clustered regularly interspaced short
palindromic repeat (CRISPR)/Cas system [13] can be applied to hPSCs
in the presence of a donor template to either 1) create naturally
occurring mutations or 2) repair a mutation to generate isogenic
controls in hPSCs. Compared to ZFNs, TALENs are simpler to engineer
[14] and may exhibit greater speciﬁcity with less cytotoxicity [15]. The
CRISPR/Cas9 system has a signiﬁcant advantage over ZFN and TALEN
as it relies on RNA to home onto DNA whereas ZFN and TALEN depend
on custom-making proteins for each speciﬁc DNA target. Thus,
CRISPR/Cas9 is technically easier to use and is more efﬁcient at cutting
target DNA [16]. Given these advantages, coupled with the fact that the
CRISPR/Cas9 system is cost-effective and easily accessible in re-
positories such as Addgene (https://www.addgene.org/), this system
has led to an exponential increase in genome engineering of cells and
model organisms to study disease biology. The subsequent differen-
tiation of these genetically engineered hPSCs into cell types of interest
would thus facilitate the study of disease biology. We will brieﬂy
introduce each of these genome editing methodologies.
3.1. Homologous recombination (HR)/Gene targeting
Homologous recombination (HR), or gene targeting, is a method for
introducing a particular DNA sequence into a host genome (Figure 1)
[17]. When DNA double-strand breaks (DSBs) occur in cells (e.g. due to
DNA damage), the DNA can be repaired either via HR or via (error-
prone) non-homologous end joining (NHEJ) [18]. DNA repair by HR
occurs either via the double-strand break repair (DSBR) pathway or the
synthesis-dependent strand annealing (SDSA) pathway. The former
commonly results in an exchange of nucleotide sequence(s) between
the two strands of DNA (crossover), leading to genetic recombination in
contrast to the SDSA pathway, which does not result in a crossover.
The natural process of DNA damage and DSBR pathway is the con-
ventional gene targeting method to insert transgenes into the genome
without the use of nucleases (ZFNs, TALENs or CRISPR/Cas).
3.2. Zinc ﬁnger nuclease (ZFN)
The ﬁrst advancement in genome editing arose from the discovery of
zinc ﬁnger nucleases (ZFNs), synthetic restriction enzymes containing
DNA-binding domain(s) fused to a DNA-cleavage domain (typically a
non-speciﬁc cleavage domain from bacterial type IIS FokI restriction
enzyme; located at the C-terminus) [19]. These DNA-binding domains,
which contain 3e6 zinc ﬁnger repeats and are able to recognize 9e18
base pairs, allow homing to target DNA followed by DNA cleavage
(Figure 1) [20]. For DNA cleavage to occur, however, the cleavage
domain needs to dimerize, necessitating a pair of ZFNs to bind
opposite strands of DNA and ﬂank a region of interest. ZFNs induce
DNA DSBs and stimulate the endogenous DNA repair machinery [21],
which, in the presence of a homologous donor template, can result in a
replacement of the target allele. In contrast, NHEJ operates in the
absence of a homologous donor template. This strategy may be
suitable for disabling autosomal dominant mutations present in hiPSCs
derived from diseased patients.
3.3. Transcription activator-like effector nuclease (TALEN)
Following on the heels of the use of ZFNs, transcription activator-like
effector nucleases (TALENs) were discovered. TALE is a Xanthomo-
nas bacterial protein containing a domain of tandem repeats (33e34
amino acids), which can target DNA. These tandem repeats contain
repeat-variable diresidues (RVDs; 12th and 13th amino acid), which
dictate DNA-binding speciﬁcity. By combining the appropriate RVDs,
TALEs can be custom-made to target DNA. When fused to a DNA-
cleavage domain (e.g. FokI endonuclease), TALE nucleases (TALENs)
are generated [22]. Like ZFNs, a pair of TALENs induces DSBs and
relies upon HR or NHEJ, to either introduce foreign DNA for gene repair
or disrupt endogenous gene function, respectively (Figure 1).
3.4. Clustered regularly interspaced short palindromic repeat
(CRISPR)/Cas
Very recently, another technological breakthrough led to the discovery
of clustered regularly interspaced short palindromic repeats
(CRISPRs), a repetitive pattern (between 24 and 48 base pairs) in
which DNA sequences would be followed by nearly the same
sequence in reverse orientation followed by spacer DNA. This unique
pattern, ﬁrst identiﬁed in E. coli bacteria, which integrated the
Abbreviations
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TALEN transcription activator-like effector nuclease
T1D type 1 diabetes
T2D type 2 diabetes
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sequence of phages (spacer DNA) to fend off future attacks, was
often found to be associated with CRISPR-associated (Cas) genes.
Upon phage attack, the bacterium ﬁrst transcribes the spacer and
palindromic DNA into a long RNA molecule. This RNA molecule is
then cleaved by RNase III, involving Cas9 (a nuclease which has two
active sites for cutting each strand of the DNA double helix) and
trans-activating CRISPR RNA (tracrRNA), into short spacer-derived
RNA (CRISPR RNA; crRNA) in the cell [23].
tracrRNA and crRNA can now be intelligently combined into a “guide
RNA” molecule, and when combined with Cas9 could target speciﬁc
DNA and cut accurately (Figure 1) [24]. CRISPR/Cas9 has also been
modiﬁed into CRISPR interference (CRISPRi), which can reversibly turn
off genes by targeting a site without cutting it (Cas9 nuclease rendered
inactive), or the inclusion of activators or repressors (synthetic tran-
scription factors) to regulate gene activity at promoter regions [25,26].
Besides the constitutive expression of CRISPR/Cas9, there are alter-
native systems, which allow for conditional induction via the doxycy-
cline- or Tet-regulated Cas9 system. Current CRISPR/Cas systems are
from Streptococcus pyogenes, Streptococcus thermophilus, Neisseria
meningitides and Treponema denticola.
Figure 1: Genome editing methodologies which can be applied to human pluripotent stem cells. Homologous recombination (HR), or the more advanced tools such as zinc
ﬁnger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) or clustered regularly interspaced short palindromic repeat (CRISPR)/Cas system can be applied to
human pluripotent stem cells (hPSCs) either to 1) create naturally occurring mutations or 2) repair a mutation to generate isogenic controls in hPSCs, to understand the function of a
gene of interest.
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3.5. Caveats of advanced genome editing tools
Off-target effects. The DNA-binding domains of ZFNs and TALENs
need to be very speciﬁc for the target site to avoid off-target cleavage,
which results in unwanted mutations and potentially cytotoxic effects
[27]. CRISPR/Cas9 is also known to generate off-target alterations,
albeit apparently at low incidence [28,29], since mispairing is allowed
between the guide RNA and the genomic DNA. Nonetheless, caution is
required in their design and use. Some strategies involving the opti-
mization of the guide RNA/Cas9 include using of software tools to
predict potential off-target sites (http://omictools.com/crispr-cas9-
c1268-p1.html), truncating the guide RNA (<20 nucleotides) to
decrease off-target mutagenesis [30], lowering the dosage of guide
RNA and Cas9 plasmids, and decreasing the number of mismatches
between the guide RNA and the genomic DNA. A “double nick” system
with Cas9 nickase, which contains a single inactive catalytic domain,
may also be used [31e33].
Repeated cleavage of a repaired site. Due to the high cleavage
efﬁciency of these genome editing tools, there is a possibility of re-
cutting a repaired site [34]. One way to mitigate this is to introduce
silent mutations in the donor template to minimize subsequent
nuclease binding [35].
3.6. Single-stranded oligodeoxyribonucleotide (ssODN)
Since the generation of conventional donor template gene targeting
constructs for conventional HR is time consuming, single-stranded
oligodeoxyribonucleotides (ssODNs) are currently being employed
in concert with these advanced genome editing tools for high fre-
quency “footprint-free” genome editing [36]. These genome editing
tools act by introducing a sequence-speciﬁc DSB within the ssODN
homology region (thus increasing recombination frequency) and
facilitating HR via the DSBR pathway using ssODN as a template
[37].
SsODNs are short synthetic nucleotides designed to be either exactly
complementary to the target DNA sequence (for gene correction) or
contain nucleotide mismatch(es), insertions or deletions. SsODNs are
very simple to use, as opposed to conventional donor template con-
structs (plasmids or viral vectors), predicted to have high safety and
ﬁdelity with minimal immunotoxicity, and do not appear to have off-
target effects [36]. Studies combining ZFNs with ssODN were
among the ﬁrst to suggest the possibility of high frequency genome
editing [38] and have been successfully applied to Parkinson’s
disease-hiPSCs [39].
4. COUPLING HUMAN PLURIPOTENT STEM CELLS AND
GENOME EDITING TOOLS TO INVESTIGATE DIABETES AND
METABOLIC DISEASE MECHANISMS
4.1. Examples of studying disease mechanisms with hPSCs and
genome editing tools
Traditional HR can be used for gene correction to demonstrate
genotype-phenotype causality albeit with very low rates of efﬁciency.
ZFNs were ﬁrst demonstrated in 2007 to be capable of gene editing
in human embryonic stem cells (hESCs) [40]. Their ability to enhance
HR-mediated gene targeting [41,42] has led to their use in multiple
studies including targeted gene disruption at the CCR5 locus (HIV-1
resistance) [43] and correction in the a-synuclein gene (susceptibility
variant for Parkinson’s disease) [39], a1-antitrypsin [44], sickle cell
anemia mutation [35,45], gp91(phox) (X-linked chronic granuloma-
tous disease) [46], a-thalassemia genes [47] and glucokinase (GCK)
[7]. Shortly after, TALENs were employed for genetic engineering in
hPSCs [48,49] for correcting the COL7A1 [50] and a1-antitrypsin
genes [51]. Given the superior cutting efﬁciency, CRISPR/Cas9 is
increasingly becoming the favored choice for genome editing in
hPSCs [16,52].
4.2. Employing hPSCs and genome editing tools to study diabetes
and metabolic syndromes
In general, the strategy to carry out in vitro disease modeling of dia-
betes and related metabolic syndromes with hPSCs and genome
editing tools would be to 1) derive hiPSCs from patients with these
conditions, 2) generate “repaired/corrected” isogenic controls [53] and
then 3) differentiate them into pancreatic cells or target cells of rele-
vance, such as immune cells in the case of T1D or myocytes, adi-
pocytes and hepatocytes in the case of T2D (Figure 2). If patient
material is inaccessible, one could introduce (naturally occurring)
mutations or gene variants into hESCs and differentiate them
accordingly to study disease mechanisms. Since excellent reviews
have been published recently, we will provide a brief overview to
familiarize the reader with the classiﬁcation of diabetes and metabolic
disorders.
4.3. Genetic determinants of diabetes and metabolic syndromes
Diabetes is a metabolic disease characterized by uncontrolled hyper-
glycemia resulting from the variable combination of dysfunctional in-
sulin secretion by pancreatic beta cells and insulin resistance. It is
generally classiﬁed into monogenic diabetes (maturity onset diabetes
of the young [MODY], neonatal diabetes, mitochondrial diabetes
[54,55], syndromes of insulin resistance) [56], type 1 diabetes (T1D)
and type 2 diabetes (T2D). The metabolic syndrome is a combination of
conditions including central obesity (as measured by waist circum-
ference), dyslipidemia (high triglycerides, reduced high density lipo-
protein cholesterol), hypertension and elevated fasting plasma glucose.
These conditions increase the risk of diabetes and atherosclerotic
vascular disease. The genetic variants responsible for monogenic
diabetes are typically rare and have high penetrance whereas the
variants involved in the etiology of the complex forms of T1D and T2D
are relatively common and have low penetrance. Some of the known
genetic determinants of each of these types of diabetes and metabolic
syndromes are summarized in Table 1.
4.3.1. MODY, neonatal diabetes and mitochondrial diabetes
Patients with MODY, neonatal diabetes and mitochondrial diabetes
(Table 1) commonly exhibit impairments in one or more of the three
main beta cell functions: 1) glucose sensing, 2) making and storing
insulin, and 3) secreting insulin on demand. For instance, mutations in
genes such as GCK [57] and glucose transporter SLC2A2 (also known
as GLUT2) [58] result in altered glucose sensing, which, in turn, results
in an increased blood glucose threshold for insulin secretion,
decreased hepatic glycogen storage, and increased hepatic gluco-
neogenesis [59e61]. Mutations in several transcription factors result
in defects in pancreatic beta cell development, which directly impact
insulin synthesis and function while mutations in the insulin gene (INS)
obviously affect the key hormone made by pancreatic beta cells [62].
ATP synthesis defect (mitochondrial diabetes) and mutations in ATP-
sensitive potassium channel subunits (channel-building Kir6.2 [po-
tassium inwardly-rectifying channel, subfamily J, member 11;
KCNJ11] and regulatory SUR1 [ATP-binding cassette transporter
subfamily C member 8], ABCC8) all affect insulin secretion [63].
One strategy to study these monogenic syndromes would be to derive
hiPSCs from these patients [105], differentiate them into pancreatic
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progenitors and then transplant these progenitors into immunocom-
promised (SCID-Beige or NSG) mice for in vivo maturation (Figure 2).
This methodology has been recently used to successfully model
MODY2, demonstrating that beta cells derived from hiPSCs with GCK
mutation are indeed less sensitive to glucose levels [7]. Endoplasmic
reticulum (ER) stress-related diabetes in patients with Wolfram syn-
drome has also been modeled using hiPSC-derived beta cells,
demonstrating that WFS1 protein maintains ER function in beta cells by
acting upstream of the unfolded protein response (UPR) pathways [8].
These two studies indicate that hiPSC-derived beta cells can indeed
recapitulate diabetic phenotypes occurring in humans. Likewise, the
stepwise analysis of human pancreatic development with this strategy
would likely provide mechanistic insights into the ability of a single
gene mutation (PDX1, PTF1A, HNF1B, GATA6 and GATA4) to promote
pancreatic agenesis/atrophy. Further, studying mutations in KCNJ11
and ABCC8 using hiPSC-derived beta cells may elucidate the mech-
anistic differences between permanent and transient neonatal diabetes
[64]. Overall, insulin production and secretion could be compared
between diseased and gene-corrected pancreatic cells to understand
the underlying cause of each type of monogenic diabetes (Figure 2).
Figure 2: Schematic showing the use of human pluripotent stem cells from patients with diabetes and metabolic diseases to study disease mechanisms in vitro.
Human induced pluripotent stem cells (hiPSCs) derived from patients with monogenic diabetes, syndromes of insulin resistance, type 1 diabetes (T1D), type 2 diabetes (T2D) and
metabolic syndromes can be differentiated into pancreatic cells, skeletal myocyotes, hepatic cells, adipocytes and immune cells, where relevant, to study disease mechanisms
in vitro.
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Table 1 e Genetic determinants of diabetes and metabolic syndromes.
Monogenic forms of diabetes
Type of monogenic diabetes Gene(s)
MODY MODY1 (HNF4A)(>30 mutations)
MODY2 (GCK)(>600 mutations)
MODY3 (HNF1A)(>200 mutations)
MODY4 (PDX1)
MODY5 (HNF1B)(>65 mutations)
MODY6 (NEUROD1), MODY7 (KLF11), MODY8 (CEL), MODY9 (PAX4), MODY10 (INS),
MODY11 (BLK), MODYX (GATA6), MODYX (ABCC8)
Neonatal diabetes KCNJ11, ABCC8 and many others
Mitochondrial diabetes tRNA(Leu)(UUR)(A3243G)
Syndromes of insulin resistance Defects in insulin signaling pathway Donohue syndrome, Rabson-Mendenhall syndrome, Type A insulin resistance (INSR)
AKT2, TBC1D4
Lipoatrophic diabetes Congenital generalized lipodystrophy (AGPAT2, BSCL2, PTRF, CAV1)
Familial partial lipodystrophy (LMNA, PPARG, AKT2, CIDEC, PLIN1)
Monogenic forms of obesity LEP, LEPR, POMC, PCSK1, MC4R, SIM1, BDNF, NTRK2
Type 1 diabetes (T1D)
Candidate gene(s) Speciﬁc associated variant(s)/single nucleotide polymorphisms (SNPs)
HLA DR-DQ, HLA-B, HLA-A, INS
PTPN22 R620W, 1858C/T
IL2RA/CD25 rs706778, rs3118470, rs41295061, rs35285258
CTLA4 A17T
IFIH1/MDA5 rs1990760
CLEC16A/KIAA0350 rs2903692, rs725613, rs17673553
ERBB3 rs2271189, rs11171747, rs2292399
PTPN2 rs2542151, rs1893217
UBASH3A/STS2 T946A
IL18 rs1946519, rs1946518, rs187238
RANTES rs4251719, rs2306630, rs2107538
VDR rs1544410, rs2228570
CIITA rs11074932, rs3087456
CYP27B1 rs4646536
EFR3B rs478222
CD226 rs763361
LMO7 rs539514
DLK1 rs941576
SLC11A1 rs3731685
SH2B3, IL27, BACH2, PRKCQ, IL10, CD69, CYP27B1, CTSH, TNFAIP3, STAT4, IL18RAP,
TAGAP, RNLS, IL2, C1QTNF6, CRYAB, CTBR2, ERAP1/ARTS1, FHOD3, GLIS3, HERC2,
HTR1A, IL19, IL20, IL26, ITPR3, PIP4K2C, RASGRP1, RFN180, RGS1, SIRPG, SKAP2,
STAT3, TNFA, TNFB, Xp22
Type 2 diabetes (T2D)
Candidate gene(s) Speciﬁc associated variant(s)/single nucleotide polymorphisms (SNPs)
TCF7L2 (strongest) rs7903146, rs7901695, rs12255372, rs10885409, rs12573128
PPARG Pro12Ala (P12A)/rs1801282
KCNJ11 Glu23Lys (E23K)/rs5219, C42R
HHEX/IDE rs1111875, rs7923837, rs5015480, rs7923837
SLC30A8 Arg325Trp/rs13266634, rs3802177, rs2466293
CDKAL1 rs7756992, rs7754840, rs10946398, rs9465871, rs4712523, rs4712524, rs6931514
IGF2BP2 rs4402960, rs1470579, rs6769511
CDKN2A/B rs10811661, rs1412829
ABCC8 Ala1369Ser (A1369S)/rs757110, Y356C
MTNR1B/ADCY5 rs10830963, rs1387153, rs2877716, rs1374645, rs2166706, rs10930963
KCNQ1 rs2237892, rs2237895, rs2237897, rs231362, rs2283228, rs163182, rs2299620
GCKR P446L, rs780094, rs1260326
GCK rs1799884, -30G/A polymorphism in promoter, rs4607517
HNF1A G319S, rs7957197
ADAMTS9 rs4607103
G6PC2 rs560887, rs552976
JAZF1 rs864745
CDC123/CAMK1D rs12779790, rs10906115
IRS1 rs2943641
WFS1 rs4689388, rs1801214
DUSP9 rs5945326
KLF14 rs972283, rs4731702
C2CD4A/C2CD4B rs1436955, rs1370176, rs1436953, rs7172432
PTPRD rs17584499
PROX1 rs340874
BCL11A rs10490072
RBMS1 rs7593730
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Table 1 e (continued )
THADA Thr1187Ala/rs7578597
ARAP1 (formerly CENTD2) rs1552224
IGFBP2 rs1470579
PAX4 rs10229583
PAX6 rs685428
VEGFA rs9472138
VEGF rs6921438
HNF1B, HNF4A, DGKB/TMEM195, HMGA2, MADD, AP3S2, CHCHD9, GRB14,
HMG20A, LARP6, SGSM2, ST6GAL1, TP53INP1, VPS26A, ZBED3, UBE2E2,
ZFAN6, TSPAN8/LGR5, NOTCH2/ADAMS30, ZFAND3
Obesity/Metabolic syndrome
Candidate gene(s) Speciﬁc associated variant(s)/single nucleotide polymorphisms (SNPs)
FTO rs8050136, rs1121980, rs17817449, rs9941349, rs3751812, rs1421085,
rs17820875, rs860713, rs1558902, rs9935401, rs9930506, rs6499640,
rs11642015, rs62048402, rs57103849, rs16945088, rs9930333, rs8057044,
rs12447427, rs7202116
MC4R rs17782313, rs12970134, rs17700633, rs571312, rs17773430, rs11872992,
rs17782312, rs1942872
TMEM18 rs6548238, rs7561317, rs4854344, rs2867125
NEGR1 rs2815752, rs3101336, rs9424977, rs2568958
GNPDA2 rs10938397
SH2B1 rs7498665, rs4788102, rs7201929, rs147094247, rs60604881, rs62037368,
rs62037369
KCTD15 rs29941
MTCH2 rs4752856, rs10838738, rs3817334, rs7120548
BDNF rs925946, rs6265, rs4923461, rs10968576, rs988712
SEC16B rs10913469, rs543874
APOA5 rs662799
FAIM2/BCDIN3 rs7138803, rs7132908
TFAP2B rs987237
QPCTL/GIPR rs2287019, rs10423928
LYPLAL1/SLC30A10 rs4846567, rs2605100, rs11118316
HMGCR rs7703051, rs12654264, rs3846663, rs3846662
PTP-1B/PTPN1 rs718049, rs2282146, rs1885177, 1484insG, P303P, P387L
CD36 rs1049673, rs3211931, rs3211938, rs1194197, rs1761667
SFRS10-ETV5-DGKG rs7647305
MSRA/TNKS rs545854
NPC1 rs1805081
MAP2K5/SKOR1 rs2241423
NRXN3 rs10146997, rs11624704
PCSK1 rs6235, rs1799904
GRB14 rs13389219
VEGFA rs6905288, rs9472138
INPPL1/SHIP2 rs2276047, rs9886, rs2276048
AHSG rs2077119, rs4917
GHRL rs696217, rs26802
NISCH/STAB1 rs6784615
LEPR rs1137101
ADAMTS9 rs13060013
NUDT3 rs206936
CDKAL1 rs2206734
CPEB4 rs6861681
MAF rs7192960
TNNI3K rs1514175
LPIN1 rs11693809
IL6 597 G/A, 572 G/C, 174 G/C
LEP rs10954174, rs6966536
ENPP1 rs7754561
GNAT3 rs11760281
GPR120 R270H
KLF9 rs11142387
LRP1B rs2890652
MTIF3 rs4771122
NPY L7P
PFKP rs6602024
PRKD1 rs10144903
THNSL2 rs1659258
RSPO3, ITPR2/SSPN, INSIG2, TBX15/WARS2, LY86, NFE2L3, SDCCAG8,
PTER, BEACON/UBL5, ADCY3/DNAJC27, ADIPOQ, AIF1, AKT1, BAT2,
CADM2, DNM3/PIGC, GPRC5B, GP2, HNF4A, HOXC13, KLF14, LRRN6C,
PACS1, PAX6, POMC, PRKCH, PRL, PTBP2, RBJ, RMST, SLC39A8,
TMEM160, TRK, ZNF608, ZNRF3/KREMEN1, 1q25
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4.3.2. Syndromes of insulin resistance
Syndromes due to defects in the insulin signaling pathway as well as
lipoatrophic diabetes could be modeled using hiPSC and genome
editing technologies. hiPSCs from patients with defective insulin
signaling molecules such as INSR [65], v-akt murine thymoma viral
oncogene homolog 2 (AKT2) and TBC1 domain family member 4
(TBC1D4) could be differentiated into skeletal myocytes, adipocytes,
hepatic and pancreatic cell types to study abnormalities in develop-
ment [66] (Figure 2) and to distinguish cell autonomous versus non-cell
autonomous effects. Outstanding questions that could be addressed
include: 1) studying mechanisms that underlie hyperglycemia and
hyperinsulinemia in individuals with INSR mutations, 2) dissecting the
mechanistic differences between autosomal dominant and recessive
gene mutations that cause insulin resistance of varying degrees, 3)
interrogating the role of AKT2 in beta cell function, and 4) exploring
why INSR mutations do not result in hepatosteatosis and dyslipidemia
in contrast to other forms of severe insulin resistance. hiPSCs from
patients with lipoatrophic diabetes could be differentiated into adipo-
cytes to study developmental defects (Figure 2). Monogenic forms of
insulin resistance that result into lipoatrophic diabetes can be sub-
classiﬁed into congenital generalized lipodystrophy (CGL) and familial
partial lipodystrophy (FPL) [67] (Table 1). In the former, gene mutations
typically affect various aspects of adipocyte biology such as the
biosynthesis of triglycerides [68] or adipocyte differentiation [69], and
hiPSCs from these patients could be a source for investigating the role
of the mutated genes in adipocyte biology, lipoatrophic diabetes and
insulin resistance. Considering the signiﬁcant genotypic and pheno-
typic heterogeneity in FPL, hiPSCs with LMNA and PPARG mutations
can be used to study dysfunction in fat metabolism whereas cells with
CIDEC and PLIN1 mutations can be used to study triglyceride mobili-
zation and lipid droplet dynamics.
4.3.3. Monogenic forms of obesity
Several gene mutations involved in these syndromes affect satiety and
body weight [70], making the brain-fat inter-organ cross-talk chal-
lenging to model. However, one could consider examining the effects
on adipocyte development using hiPSCs.
4.4. Employing hPSCs and genome editing tools to study type 1
diabetes (T1D)
Patients with T1D are unable to secrete insulin due to near complete
destruction of their pancreatic beta cells. More than 50 risk variants/
susceptibility alleles have been found to be associated with suscep-
tibility to this disease [71] (https://www.niddkrepository.org/studies/
t1dgc/) (Table 1). The strongest association is with the human
leukocyte antigens (HLAs), which accounts for a large proportion of the
genetic risk for T1D [71]. Most of the T1D genes affect adaptive and
innate autoimmunity leading to incomplete self-tolerance to beta cell
antigens and immune-mediated destruction of beta cells [71]. T1D-
hiPSCs can be differentiated into T lymphocytes [72e74] and
pancreatic beta cells [75e77] to allow co-culture experiments aimed
at progressively evaluating their interactions in vitro (Figure 2) [78]. A
similar strategy can be applied to hiPSCs derived from T1D-susceptible
patients to examine the impact of susceptible gene variants (Table 1)
on the vulnerability of pancreatic beta cells to immune attack. For
instance, hiPSCs derived from patients with a gene variant in PTPN22
can be differentiated into lymphocytes to study lymphocyte function
[79e81]. hiPSCs from subjects with gene variants in ERBB3, which is
expressed in monocytes and dendritic cells, and may affect antigen
presenting cell (APC) function [82], can be differentiated into selective
immune cells to study how they affect APC function. hiPSCs from
patients with gene variants in UBASH3A (also known as STS2), which
is speciﬁcally expressed in lymphocytes [83], are well suited for dif-
ferentiation into lymphocytes to study the function of this gene.
4.5. Employing hPSCs and genome editing tools to study type 2
diabetes (T2D) and metabolic syndromes
T2D results from a combination of genetic and environmental effects.
T2D patients, characterized by early insulin resistance followed by a
failure of pancreatic beta cells to compensate, develop uncontrolled
hyperglycemia. The association of obesity with insulin resistance
suggests that excess adipose tissue could contribute to the insulin
resistance [84]. The poor ability of skeletal myocytes and adipocytes
to utilize glucose and fatty acids, and to store them as glycogen and
triglycerides (respectively) in states of insulin resistance lead to hy-
perglycemia and dyslipidemia. Insulin resistant hepatocytes respond
poorly to insulin, fail to synthesize and store glycogen, and, with
rising glucagon levels, continue to produce glucose leading to hy-
perglycemia. Patients with T2D exhibit defects in glucose-stimulated
insulin secretion and a gradual decrease in pancreatic beta cell mass
that, combined, fail to sustain the increased demands of insulin
resistance. Thus, T2D-hiPSCs can be differentiated into skeletal
myocytes, adipocytes and hepatocytes to study insulin resistance
(independent of organ cross-talk) in each of these tissues, and into
pancreatic beta cells to study mechanisms underlying cell death, de-
differentiation and/or altered secretory function in T2D [85,86]
(Figure 2).
To date, at least 100 risk variants/susceptibility alleles have been
associated with T2D and/or quantitative glycemic traits (fasting
glucose, fasting insulin, HOMA-B and HOMA-IR) [87] (Table 1).
Although the cumulative effects of these variants appear to explain only
5e10 % of the familial aggregation of T2D [88], understanding the
mechanisms by which they increase T2D risk has important implica-
tions for the development of new therapies. The use of hPSCs and
advanced genome editing tools can potentially facilitate this goal. For
example, the transcription factor-7 like 2 (TCF7L2) gene, a tran-
scription factor reported to be important for beta cell survival and
function [89], contains variants that exhibit the strongest association
with T2D [90]. Gene variants in TCF7L2 inﬂuence the therapeutic
response to sulfonylureas [91] and have been demonstrated to
modulate other aspects of pancreatic islet function [92]. The poorly
understood mechanisms underlying these effects potentially could be
investigated by using hPSCs and genome editing. For instance, one
can leverage upon hiPSCs derived from T2D-susceptible patients
based on their TCF7L2 genotype, and differentiate them into pancreatic
beta cells to answer whether TCF7L2 gene variants affect development
and provide clues to the initial beta cell mass at adulthood. Related to
the two cases of hiPSC-based modeling of MODY2 [7] and Wolfram
Syndrome [8], gene variants found in GCK, GCKR and WFS1 have been
linked to T2D risk. Thus, it may be possible to extrapolate these
ﬁndings and begin investigating the functional effects of associated
gene variants. A similar approach could be adapted to investigate the
role of other variants (Table 1) with appropriate readouts. For instance,
hiPSCs with a deﬁned gene variant and their gene-corrected isogenic
control hiPSCs could be differentiated simultaneously and then sub-
jected to high throughput analyses to determine developmental or
expression proﬁle differences. This is expected to reveal gene targets
affected by the presence of the speciﬁc gene variant and could thereby
shed light on mechanistic insights into the predisposition towards T2D.
One caveat, though, would be the speciﬁc cell type of action of the
identiﬁed genome-wide association study (GWAS) gene. For example,
gene variants in the HHEX gene could possibly affect pancreatic beta
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cell, delta cell or even hepatocyte biology, thereby predisposing in-
dividuals toward developing T2D.
More than 30 risk variants/susceptibility alleles have been associated
with waist circumference, waist-hip ratio, BMI and obesity (Table 1),
and are estimated to account for 2% of the occurrence of obesity [87].
The fat mass and obesity-associated (FTO) locus exhibits a strong
association with BMI and obesity [93]. Other variants including those
found near melanocortin 4 receptor (MC4R) which can explain 2e3 %
of cases of severe obesity [94] and proopiomelanocortin (POMC) [95],
are strong biological candidates for BMI and obesity.
Compared to gene variants that affect satiety and body weight [96],
those affecting adipocyte development and function are relatively
easier to model because of a deﬁnitive readout in the latter. For
instance, FTO is a potential candidate for studies in hiPSC-derived
adipocytes since its expression has been reported to decrease dur-
ing adipocyte differentiation [97]. In common obesity, circulating leptin
(LEP) levels are high, indicating leptin resistance [98,99]. Differenti-
ating hiPSCs derived from those with risk variants in the LEP gene into
adipocytes can aid in increased understanding of leptin regulation of
adipocyte function. Genes such as TMEM18, KCTD15, MTCH2,
BCDIN3, SULT1A1, PTER, TUFM, FAIM2, BDNF, NEGR1 and NPC1 with
potential regulatory roles in the adipose tissue [100,101] could be
studied by independently differentiating hiPSCs into adipocytes to
study the speciﬁc gene function(s). In addition, TMEM18, PTER,
SULT1A1 and TUFM may be studied in hepatocytes whereas SH2B1
and TUFM could be studied in skeletal myocytes [102]. However, it
should be cautioned that genes currently associated with the risk-
conferring polymorphisms may not actually be the only genes
involved in the polymorphism, as in the case of FTO and IRX3 [103].
5. CONCLUSIONS
hPSCs and the advancing genome editing tools appear to be a timely
and potent combination for probing molecular mechanism(s) under-
lying diseases such as diabetes and metabolic syndromes. Studying
monogenic forms of diabetes and syndromes of insulin resistance
using these tools would be extremely useful given the lack of an
autoimmune attack and confounding effects of insulin resistance and
obesity. One caveat of this methodology at the moment is the “low”
efﬁciency of deriving human beta cells in vitro [75,76], possibly due to
our incomplete knowledge on human pancreatic development. Another
explanation would be the lack of in vivo environmental cues emanating
from proximal tissues such as the vasculature. Nonetheless, suc-
cessful disease modeling of MODY2 [7] and Wolfram Syndrome [8]
already suggests a high possibility of success. These technologies
have the potential to elucidate the underlying pathophysiology that
stem from defects in 1) beta cell development, metabolism or survival
or 2) development of adipocyte. For instance in the case of MODY2, it is
now clear that GCK mutation affects glucose-stimulated insulin
secretion but not insulin synthesis or beta cell proliferation [7]. With the
latest advances in the derivation of mature and functional human
pancreatic beta-like cells from hPSCs in vitro [75e77], eventually
circumventing the requirement for in vivo maturation, disease
modeling of diabetes is expected to progress exponentially. The
knowledge gained from these hiPSC-based disease modeling studies
can potentially be translated into the clinics by guiding clinicians on the
appropriate type of medication to use for each condition based on the
mechanism of action of the disease.
Findings from these proposed studies could also offer clues to the
pathophysiology of the “garden variety” of type 2 diabetes which is
known to manifest defects in each of these tissues. hPSCs and
genome editing tools may also provide an opportunity to better un-
derstand the relevance of gene variants identiﬁed from GWAS studies,
in causing T1D, T2D, obesity and metabolic syndromes, given that
they exhibit only modest effects andw85% of the variants map onto
non-coding regions such as enhancers or regulatory elements [104].
Investment into hPSCs and genome editing would allow a better
mechanistic understanding of the pathophysiology of monogenic and
complex diseases relevant for organismal homeostasis and therefore
an improved approach to stratiﬁed personalized medicine. By iden-
tifying the impact of gene variants on disease predisposition, pro-
phylactic measures in the form of lifestyle alterations or medication
could be adopted early on in life to delay or even prevent the onset of
diabetes and/or metabolic diseases. It is also likely that these hiPSC-
based disease modeling studies would provide insights into ap-
proaches to predict the susceptibility of disease. Henceforth, the
translational potential of studying human diabetes and metabolic
syndrome disease mechanisms is huge, with opportunities for early
prophylactic intervention that could have long-term implications for
global health care and reduction of economic burden. While the
derivation of hiPSCs from human tissues is relatively easier and
gaining popularity compared to just a few years ago [2], it is likely
that the modern technology of generating site-speciﬁc nucleases will
also rapidly mature to make in vitro disease modeling a routine
approach.
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